tenecteplase – Medxy AI

Early Recanalization in Distal and Medium Vessel Occlusion Strokes: Tenecteplase vs Alteplase

By MedXY 09/15/2026

In patients with distal and medium vessel occlusion strokes, tenecteplase achieves higher early recanalization rates and reduces early infarct growth compared to alteplase, supporting its preferential use in this clinical setting.

Clinical Updates Neurology news

Tenecteplase Efficacy in Distal Cerebral Artery Occlusions: Insights From the Secondary Analysis of the TASTE Randomized Clinical Trial

By MedXY 09/09/2026

Secondary analysis of the TASTE trial reveals tenecteplase confers superior functional outcomes versus alteplase in patients with distal middle cerebral artery occlusions, supporting its use in more peripheral ischemic stroke territories.

Neurology news

Baseline Ischemic Burden Influences Tenecteplase Benefit Before Thrombectomy in Acute Stroke: Insights from the BRIDGE-TNK Trial

By MedXY 08/22/2026

A post hoc analysis of the BRIDGE-TNK trial reveals that intravenous tenecteplase before endovascular thrombectomy significantly improves functional independence in acute large-vessel occlusion stroke patients with extensive baseline ischemia (ASPECTS <8), while no benefit and potential risks occur in those with minor ischemia (ASPECTS 8-10).

Neurology news

Successful Recanalization Boosts Functional Recovery in Minor Ischemic Stroke: Insights from the TEMPO-2 Trial

By MedXY 06/27/2026

Secondary analysis of the TEMPO-2 trial reveals that successful recanalization significantly improves 90-day functional outcomes in minor ischemic stroke patients with proven occlusion, with tenecteplase markedly enhancing recanalization rates compared to standard care.

Neurology news

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial

By MedXY 06/03/2026

In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.

Neurology news

Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial

By MedXY 06/03/2026

In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.

Neurology news

Tenecteplase Improves 90-Day Functional Outcomes in Basilar Artery Occlusion Within a 24-Hour Window: Results from TRACE-5

By MedXY 02/16/2026

The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high-mortality condition.

Neurology news Radiology

Expanding the Thrombolysis Window: Tenecteplase Improves Outcomes in Late-Window Non-Large Vessel Occlusion Stroke

By MedXY 02/08/2026

The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptomatic intracranial hemorrhage compared to standard care.

Neurology news Ophthalmology

Tenecteplase Fails to Improve Visual Outcomes in Acute Central Retinal Artery Occlusion: Results from the TenCRAOS Trial

By MedXY 02/02/2026

The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal intracranial hemorrhage.

Cardiology news

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial

By MedXY 01/16/2026

The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis, potentially redefining the standard of care.

Neurology news

Reevaluating Intravenous Tenecteplase in Minor Disabling Stroke: Insights from the TEMPO-2 Secondary Analysis

By MedXY 10/29/2025

A secondary analysis of the TEMPO-2 trial shows that intravenous tenecteplase does not improve 90-day outcomes in minor disabling stroke defined by NIHSS scores, highlighting the need to reconsider thrombolysis in this patient population.

Neurology Specialties

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials

By MedXY 08/01/2025

Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusion.

Clinical Updates Neurology news Specialties

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

By MedXY 07/31/2025

The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant benefit.

Clinical Updates news

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

By MedXY 07/31/2025